|
1
|
Naito Y, Yoshioka Y, Yamamoto Y and Ochiya
T: How cancer cells dictate their microenvironment: Present roles
of extracellular vesicles. Cell Mol Life Sci. 74:697–713.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Maman S and Witz IP: A history of
exploring cancer in context. Nat Rev Cancer. 18:359–376.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sharma P and Allison JP: Immune checkpoint
targeting in cancer therapy: Toward combination strategies with
curative potential. Cell. 161:205–214. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bejarano L, Jordāo MJC and Joyce JA:
Therapeutic targeting of the tumor microenvironment. Cancer Discov.
11:933–959. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chung HC, Ros W, Delord JP, Perets R,
Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L,
Zeigenfuss S, et al: Efficacy and safety of pembrolizumab in
previously treated advanced cervical cancer: Results from the phase
II KEYNOTE-158 Study. J Clin Oncol. 37:1470–1478. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Koh WJ, Abu-Rustum NR, Bean S, Bradley K,
Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, et al: Cervical
Cancer, Version 3.2019, NCCN clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 17:64–84. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li X, Shao C, Shi Y and Han W: Lessons
learned from the blockade of immune checkpoints in cancer
immunotherapy. J Hematol Oncol. 11(31)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Matanes E and Gotlieb WH: Immunotherapy of
gynecological cancers. Best Pract Res Clin Obstet Gynaecol.
60:97–110. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Duranti S, Pietragalla A, Daniele G, Nero
C, Ciccarone F, Scambia G and Lorusso D: Role of immune checkpoint
inhibitors in cervical cancer: From preclinical to clinical data.
Cancers (Basel). 13(2089)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ventriglia J, Paciolla I, Pisano C, Cecere
SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G,
Setola SV, et al: Immunotherapy in ovarian, endometrial and
cervical cancer: State of the art and future perspectives. Cancer
Treat Rev. 59:109–116. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sasada T and Suekane S: Variation of
tumor-infiltrating lymphocytes in human cancers: Controversy on
clinical significance. Immunotherapy. 3:1235–1251. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Murphy KM and Reiner SL: The lineage
decisions of helper T cells. Nat Rev Immunol. 2:933–944.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Szabo SJ, Dighe AS, Gubler U and Murphy
KM: Regulation of the interleukin (IL)-12R beta 2 subunit
expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med.
185:817–824. 1997.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xu D, Chan WL, Leung BP, Hunter D, Schulz
K, Carter RW, McInnes IB, Robinson JH and Liew FY: Selective
expression and functions of interleukin 18 receptor on T helper
(Th) type 1 but not Th2 cells. J Exp Med. 188:1485–1492.
1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sallusto F, Lenig D, Mackay CR and
Lanzavecchia A: Flexible programs of chemokine receptor expression
on human polarized T helper 1 and 2 lymphocytes. J Exp Med.
187:875–883. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Loetscher P, Uguccioni M, Bordoli L,
Baggiolini M, Moser B, Chizzolini C and Dayer JM: CCR5 is
characteristic of Th1 lymphocytes. Nature. 391:344–345.
1998.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Austrup F, Vestweber D, Borges E, Löhning
M, Bräuer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A
and Hamann A: P- and E-selectin mediate recruitment of T-helper-1
but not T-helper-2 cells into inflammed tissues. Nature. 385:81–83.
1997.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Basu A, Ramamoorthi G, Albert G, Gallen C,
Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ and Kodumudi K:
Differentiation and Regulation of TH cells: A balancing Act for
cancer immunotherapy. Front Immunol. 12(669474)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hung K, Hayashi R, Lafond-Walker A,
Lowenstein C, Pardoll D and Levitsky H: The Central Role of CD4+ T
cells in the antitumor immune response. J Exp Med. 188:2357–2368.
1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim WS, Shin MK and Shin SJ: MAP1981c, a
Putative Nucleic Acid-Binding Protein, Produced by Mycobacterium
avium subsp. paratuberculosis, Induces Maturation of Dendritic
Cells and Th1-Polarization. Front Cell Infect Microbiol.
8(206)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bongiorno EK, Garcia SA, Sauma S and
Hooper DC: Type 1 immune mechanisms driven by the response to
infection with attenuated rabies virus result in changes in the
immune bias of the tumor microenvironment and necrosis of mouse
GL261 brain tumors. J Immunol. 198:4513–4523. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhu S, Wang X, Wang J, Lin J, Cong Y and
Qiao G: CD21lo/medCD27+ proinflammatory B cells are
enriched in breast cancer patients and promote antitumor T cell
responses. Exp Cell Res. 361:149–154. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zou JY, Su CH, Luo HH, Lei YY, Zeng B, Zhu
HS and Chen ZG: Curcumin converts Foxp3+ regulatory T cells to T
helper 1 cells in patients with lung cancer. J Cell Biochem.
119:1420–1428. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Martinez FO, Helming L, Milde R, Varin A,
Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, et
al: Genetic programs expressed in resting and IL-4 alternatively
activated mouse and human macrophages: Similarities and
differences. Blood. 121:e57–e69. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Badylak SF, Valentin JE, Ravindra AK,
McCabe GP and Stewart-Akers AM: Macrophage phenotype as a
determinant of biologic scaffold remodeling. Tissue Eng Part A.
14:1835–1842. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Spiller KL, Anfang RR, Spiller KJ, Ng J,
Nakazawa KR, Daulton JW and Vunjak-Novakovic G: The role of
macrophage phenotype in vascularization of tissue engineering
scaffolds. Biomaterials. 35:4477–4488. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gordon S, Plüddemann A and Martinez
Estrada F: Macrophage heterogeneity in tissues: Phenotypic
diversity and functions. Immunol Rev. 262:36–55. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wilson HM: SOCS proteins in macrophage
polarization and function. Front Immunol. 5(357)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stöger JL, Gijbels MJ, van der Velden S,
Manca M, van der Loos CM, Biessen EA, Daemen MJ, Lutgens E and de
Winther MP: Distribution of macrophage polarization markers in
human atherosclerosis. Atherosclerosis. 225:461–468.
2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mills CD: Anatomy of a discovery: m1 and
m2 macrophages. Front Immunol. 6(212)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xiang W, Shi R, Kang X, Zhang X, Chen P,
Zhang L, Hou A, Wang R, Zhao Y, Zhao K, et al: Monoacylglycerol
lipase regulates cannabinoid receptor 2-dependent macrophage
activation and cancer progression. Nat Commun.
9(2574)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Slaney CY, Kershaw MH and Darcy PK:
Trafficking of T cells into tumors. Cancer Res. 74:7168–7174.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mellor AL and Munn DH: Creating immune
privilege: Active local suppression that benefits friends, but
protects foes. Nat Rev Immunol. 8:74–80. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kaech SM and Cui W: Transcriptional
control of effector and memory CD8+ T cell differentiation. Nat Rev
Immunol. 12:749–761. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wongtrakoongate P: Epigenetic therapy of
cancer stem and progenitor cells by targeting DNA methylation
machineries. World J Stem Cells. 7:137–148. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10.
2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Racioppi L, Nelson ER, Huang W, Mukherjee
D, Lawrence SA, Lento W, Masci AM, Jiao Y, Park S, York B, et al:
CaMKK2 in myeloid cells is a key regulator of the
immune-suppressive microenvironment in breast cancer. Nat Commun.
10(2450)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang HL, Hou SY, Li HB, Qiu JP, Bo L and
Mao CP: Biological function and mechanism of long noncoding RNAs
nuclear-enriched abundant transcript 1 in development of cervical
cancer. Chin Med J (Engl). 131:2063–2070. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bordon Y: Dendritic cells: Sorting,
sorted! Nat Rev Immunol. 16(657)2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hildner K, Edelson BT, Purtha WE, Diamond
M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER,
Diamond MS, et al: Batf3 deficiency reveals a critical role for
CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science.
322:1097–1100. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gardner A and Ruffell B: Dendritic cells
and cancer immunity. Trends Immunol. 37:855–865. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Swiecki M and Colonna M: The multifaceted
biology of plasmacytoid dendritic cells. Nat Rev Immunol.
15:471–485. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Guilliams M, Dutertre CA, Scott CL,
McGovern N, Sichien D, Chakarov S, Van Gassen S, Chen J, Poidinger
M, De Prijck S, et al: Unsupervised high-dimensional analysis
aligns dendritic cells across tissues and species. Immunity.
45:669–684. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ma DY and Clark EA: The role of CD40 and
CD154/CD40L in dendritic cells. Semin Immunol. 21:265–272.
2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pasqual G, Chudnovskiy A, Tas JMJ, Agudelo
M, Schweitzer LD, Cui A, Hacohen N and Victora GD: Monitoring T
cell-dendritic cell interactions in vivo by intercellular enzymatic
labelling. Nature. 553:496–500. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zanoni I, Tan Y, Di Gioia M, Broggi A,
Ruan J, Shi J, Donado CA, Shao F, Wu H, Springstead JR and Kagan
JC: An endogenous caspase-11 ligand elicits interleukin-1 release
from living dendritic cells. Science. 352:1232–1236.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zitvogel L and Kroemer G: CD103 +
Dendritic Cells Producing Interleukin-12 in Anticancer
Immunosurveillance. Cancer Cell. 26:591–593. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang
S and Li Y: Targeting the IDO1 pathway in cancer: From bench to
bedside. J Hematol Oncol. 11(100)2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Marciscano AE and Anandasabapathy N: The
role of dendritic cells in cancer and anti-tumor immunity. Semin
Immunol. 52(101481)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chomarat P, Banchereau J, Davoust J and
Palucka AK: IL-6 switches the differentiation of monocytes from
dendritic cells to macrophages. Nat Immunol. 1:510–514.
2000.PubMed/NCBI View
Article : Google Scholar
|
|
54
|
Kel JM, Girard-Madoux MJ, Reizis B and
Clausen BE: TGF-beta is required to maintain the pool of immature
Langerhans cells in the epidermis. J Immunol. 185:3248–3255.
2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Yang AS and Lattime EC: Tumor-induced
interleukin 10 suppresses the ability of splenic dendritic cells to
stimulate CD4 and CD8 T-cell responses. Cancer Res. 63:2150–2157.
2003.PubMed/NCBI
|
|
56
|
Shi Y, Yu P, Zeng D, Qian F, Lei X, Zhao
Y, Tang B, Hao Y, Luo H, Chen J and Tan Y: Suppression of vascular
endothelial growth factor abrogates the immunosuppressive
capability of murine gastric cancer cells and elicits antitumor
immunity. FEBS J. 281:3882–3893. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Huang LY, Reis e Sousa C, Itoh Y, Inman J
and Scott DE: IL-12 induction by a TH1-inducing adjuvant in vivo:
Dendritic cell subsets and regulation by IL-10. J Immunol.
167:1423–1430. 2001.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Oderup C, Cederbom L, Makowska A, Cilio CM
and Ivars F: Cytotoxic T lymphocyte antigen-4-dependent
down-modulation of costimulatory molecules on dendritic cells in
CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology.
118:240–249. 2006.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Gallois A and Bhardwaj N: Dendritic
cell-targeted approaches to modulate immune dysfunction in the
tumor microenvironment. Front Immunol. 4(436)2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Campbell KS and Hasegawa J: Natural killer
cell biology: An update and future directions. J Allergy Clin
Immunol. 132:536–544. 2013.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Caligiuri MA: Human natural killer cells.
Blood. 112:461–469. 2008.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Barrow AD, Martin CJ and Colonna M: The
Natural Cytotoxicity Receptors in Health and Disease. Front
Immunol. 10(909)2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Goding SR, Yu S, Bailey LM, Lotze MT and
Basse PH: Adoptive transfer of natural killer cells promotes the
anti-tumor efficacy of T cells. Clin Immunol. 177:76–86.
2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Overacre-Delgoffe AE, Chikina M, Dadey RE,
Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK,
Sander C, et al: Interferon-γ Drives Treg fragility to
promote anti-tumor immunity. Cell. 169:1130–1141.e11.
2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Nikzad R, Angelo LS, Aviles-Padilla K, Le
DT, Singh VK, Bimler L, Vukmanovic-Stejic M, Vendrame E, Ranganath
T, Simpson L, et al: Human natural killer cells mediate adaptive
immunity to viral antigens. Sci Immunol. 4(eaat8116)2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Tong L, Jiménez-Cortegana C, Tay AHM,
Wickström S, Galluzzi L and Lundqvist A: NK cells and solid tumors:
Therapeutic potential and persisting obstacles. Mol Cancer.
21(206)2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Habif G, Crinier A, André P, Vivier E and
Narni-Mancinelli E: Targeting natural killer cells in solid tumors.
Cell Mol Immunol. 16:415–422. 2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Hoechst B, Voigtlaender T, Ormandy L,
Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten
TF and Korangy F: Myeloid derived suppressor cells inhibit natural
killer cells in patients with hepatocellular carcinoma via the
NKp30 receptor. Hepatology. 50:799–807. 2009.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hasmim M, Messai Y, Ziani L, Thiery J,
Bouhris JH, Noman MZ and Chouaib S: Critical role of tumor
microenvironment in shaping NK cell functions: Implication of
hypoxic stress. Front Immunol. 6(482)2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Castriconi R, Cantoni C, Della Chiesa M,
Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L
and Moretta A: Transforming growth factor beta 1 inhibits
expression of NKp30 and NKG2D receptors: Consequences for the
NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA.
100:4120–4125. 2003.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Balsamo M, Scordamaglia F, Pietra G,
Manzini C, Cantoni C, Boitano M, Queirolo P, Vermi W, Facchetti F,
Moretta A, et al: Melanoma-associated fibroblasts modulate NK cell
phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA.
106:20847–20852. 2009.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Li T, Yang Y, Hua X, Wang G, Liu W, Jia C,
Tai Y, Zhang Q and Chen G: Hepatocellular carcinoma-associated
fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer
Lett. 318:154–161. 2012.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Jourdan P, Abbal C, Noraz N, Hori T,
Uchiyama T, Vendrell JP, Bousquet J, Taylor N, Pène J and Yssel H:
IL-4 induces functional cell-surface expression of CXCR4 on human T
cells. J Immunol. 160:4153–4157. 1998.PubMed/NCBI
|
|
74
|
Sallusto F, Mackay CR and Lanzavecchia A:
Selective expression of the eotaxin receptor CCR3 by human T helper
2 cells. Science. 277:2005–2007. 1997.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Zingoni A, Soto H, Hedrick JA,
Stoppacciaro A, Storlazzi CT, Sinigaglia F, D'Ambrosio D, O'Garra
A, Robinson D, Rocchi M, et al: The chemokine receptor CCR8 is
preferentially expressed in Th2 but not Th1 cells. J Immunol.
161:547–551. 1998.PubMed/NCBI
|
|
76
|
Nagata K, Tanaka K, Ogawa K, Kemmotsu K,
Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K and Takano
S: Selective expression of a novel surface molecule by human Th2
cells in vivo. J Immunol. 162:1278–1286. 1999.PubMed/NCBI
|
|
77
|
Lauerova L, Dusek L, Simickova M, Kocák I,
Vagundová M, Zaloudík J and Kovarík J: Malignant melanoma
associates with Th1/Th2 imbalance that coincides with disease
progression and immunotherapy response. Neoplasma. 49:159–166.
2002.PubMed/NCBI
|
|
78
|
Savetsky IL, Ghanta S, Gardenier JC,
Torrisi JS, García Nores GD, Hespe GE, Nitti MD, Kataru RP and
Mehrara BJ: Th2 cytokines inhibit lymphangiogenesis. PLoS One.
10(e0126908)2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Nelms K, Keegan AD, Zamorano J, Ryan JJ
and Paul WE: THE IL-4 RECEPTOR: Signaling mechanisms and biologic
functions. Annu Rev Immunol. 17:701–738. 1999.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Steidl C, Connors JM and Gascoyne RD:
Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence
of the importance of the microenvironment. J Clin Oncol.
29:1812–1826. 2011.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang
Z, Kan Q, Liu Z and Liu Y: Il-21 enhances NK cell activation and
cytolytic activity and induces Th17 cell differentiation in
inflammatory bowel disease. Inflamm Bowel Dis. 15:1133–1144.
2009.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of CD4+CD25+ regulatory
T cells. Nat Immunol. 4:330–336. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
83
|
Hori S, Nomura T and Sakaguchi S: Control
of Regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Kondrack RM, Harbertson J, Tan JT, McBreen
ME, Surh CD and Bradley LM: Interleukin 7 regulates the survival
and generation of memory CD4 cells. J Exp Med. 198:1797–1806.
2003.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Dilek N, Poirier N, Hulin P, Coulon F,
Mary C, Ville S, Vie H, Clémenceau B, Blancho G and Vanhove B:
Targeting CD28, CTLA-4 and PD-L1 Costimulation Differentially
Controls Immune Synapses and Function of Human Regulatory and
Conventional T-Cells. PLoS One. 8(e83139)2013.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Cohen AD, Schaer DA, Liu C, Li Y,
Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales
MA, et al: Agonist Anti-GITR monoclonal antibody induces melanoma
tumor immunity in mice by altering regulatory T cell stability and
intra-tumor accumulation. PLoS One. 5(e10436)2010.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Hemon P, Jean-Louis F, Ramgolam K,
Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F,
Al-Daccak R and Michel L: MHC class II engagement by its ligand
LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J
Immunol. 186:5173–5183. 2011.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Paluskievicz CM, Cao X, Abdi R, Zheng P,
Liu Y and Bromberg JS: T regulatory cells and priming the
suppressive tumor microenvironment. Front Immunol.
10(2453)2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Shan F, Somasundaram A, Bruno TC, Workman
CJ and Vignali DAA: Therapeutic targeting of regulatory T cells in
cancer. Trends Cancer. 8:944–961. 2022.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Curran MA, Montalvo W, Yagita H and
Allison JP: PD-1 and CTLA-4 combination blockade expands
infiltrating T cells and reduces regulatory T and myeloid cells
within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280.
2010.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Goldberg MV and Drake CG: LAG-3 in cancer
immunotherapy. Curr Top Microbiol Immunol. 344:269–278.
2011.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Cullen SP, Brunet M and Martin SJ:
Granzymes in cancer and immunity. Cell Death Differ. 17:616–623.
2010.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Mittal SK, Cho KJ, Ishido S and Roche PA:
Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I
induction regulates antigen presentation by macrophages but not
dendritic cells. J Biol Chem. 290:27158–27167. 2015.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Wrzesinski SH, Wan YY and Flavell RA:
Transforming growth factor-beta and the immune response:
Implications for anticancer therapy. Clin Cancer Res. 13:5262–5270.
2007.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Pylayeva-Gupta Y: Molecular pathways:
Interleukin-35 in autoimmunity and cancer. Clin Cancer Res.
22:4973–4978. 2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Lim HW, Hillsamer P, Banham AH and Kim CH:
Cutting edge: Direct suppression of B cells by CD4+ CD25+
regulatory T cells. J Immunol. 175:4180–4183. 2005.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Vasconcelos DP, Costa M, Amaral IF,
Barbosa MA, Águas AP and Barbosa JN: Modulation of the inflammatory
response to chitosan through M2 macrophage polarization using
pro-resolution mediators. Biomaterials. 37:116–123. 2015.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Porta C, Riboldi E, Ippolito A and Sica A:
Molecular and epigenetic basis of macrophage polarized activation.
Semin Immunol. 27:237–248. 2015.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Che F, Heng X, Zhang H, Su Q, Zhang B,
Chen Y, Zhang Z, Du Y and Wang L: Novel B7-H4-mediated crosstalk
between human non-Hodgkin lymphoma cells and tumor-associated
macrophages leads to immune evasion via secretion of IL-6 and
IL-10. Cancer Immunol Immunother. 66:717–729. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L,
Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial
ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog.
55:1688–1699. 2016.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Goswami KK, Ghosh T, Ghosh S, Sarkar M,
Bose A and Baral R: Tumor promoting role of anti-tumor macrophages
in tumor microenvironment. Cell Immunol. 316:1–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Hesse M, Modolell M, La Flamme AC, Schito
M, Fuentes JM, Cheever AW, Pearce EJ and Wynn TA: Differential
regulation of nitric oxide synthase-2 and arginase-1 by type 1/type
2 cytokines in vivo: Granulomatous pathology is shaped by the
pattern of L-arginine metabolism. J Immunol. 167:6533–6544.
2001.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Rodriguez PC, Quiceno DG, Zabaleta J,
Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J,
Sotomayor EM, et al: Arginase I production in the tumor
microenvironment by mature myeloid cells inhibits T-cell receptor
expression and antigen-specific T-cell responses. Cancer Res.
64:5839–5849. 2004.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Dallavalasa S, Beeraka NM, Basavaraju CG,
Tulimilli SV, Sadhu SP, Rajesh K, Aliev G and Madhunapantula SV:
The role of tumor associated macrophages (TAMs) in cancer
progression, chemoresistance, angiogenesis and metastasis-current
status. Curr Med Chem. 28:8203–8236. 2021.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-Associated macrophages in tumor immunity. Front Immunol.
11(583084)2020.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Liu C, Chikina M, Deshpande R, Menk AV,
Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, et al:
Treg cells promote the SREBP1-Dependent metabolic fitness of
tumor-promoting macrophages via repression of CD8 + T cell-derived
interferon-γ. Immunity. 51:381–397.e6. 2019.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Kumar V, Cheng P, Condamine T, Mony S,
Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G,
Penman E, et al: CD45 phosphatase inhibits STAT3 transcription
factor activity in myeloid cells and promotes tumor-associated
macrophage differentiation. Immunity. 44:303–315. 2016.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Marvel D and Gabrilovich DI:
Myeloid-derived suppressor cells in the tumor microenvironment:
Expect the unexpected. J Clin Invest. 125:3356–3364.
2015.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Greten TF, Manns MP and Korangy F: Myeloid
derived suppressor cells in human diseases. Int Immunopharmacol.
11:802–807. 2011.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Filipazzi P, Huber V and Rivoltini L:
Phenotype, function and clinical implications of myeloid-derived
suppressor cells in cancer patients. Cancer Immunol Immunother.
61:255–263. 2012.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Li H, Han Y, Guo Q, Zhang M and Cao X:
Cancer-expanded myeloid-derived suppressor cells induce anergy of
NK cells through membrane-bound TGF-beta 1. J Immunol. 182:240–249.
2009.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Liu C, Yu S, Kappes J, Wang J, Grizzle WE,
Zinn KR and Zhang HG: Expansion of spleen myeloid suppressor cells
represses NK cell cytotoxicity in tumor-bearing host. Blood.
109:4336–4342. 2007.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Sinha P, Clements VK, Bunt SK, Albelda SM
and Ostrand-Rosenberg S: Cross-talk between myeloid-derived
suppressor cells and macrophages subverts tumor immunity toward a
type 2 response. J Immunol. 179:977–983. 2007.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Rodriguez PC, Quiceno DG and Ochoa AC:
l-arginine availability regulates T-lymphocyte cell-cycle
progression. Blood. 109:1568–1573. 2007.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Srivastava MK, Sinha P, Clements VK,
Rodriguez P and Ostrand-Rosenberg S: Myeloid-derived suppressor
cells inhibit T-cell activation by depleting cystine and cysteine.
Cancer Res. 70:68–77. 2010.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Harari O and Liao JK: Inhibition of MHC II
gene transcription by nitric oxide and antioxidants. Curr Pharm
Des. 10:893–898. 2004.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Dugast AS, Haudebourg T, Coulon F, Heslan
M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H,
Martinet B, et al: Myeloid-derived suppressor cells accumulate in
kidney allograft tolerance and specifically suppress effector T
cell expansion. J Immunol. 180:7898–7906. 2008.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Kusmartsev S, Nefedova Y, Yoder D and
Gabrilovich DI: Antigen-specific inhibition of CD8+ T cell response
by immature myeloid cells in cancer is mediated by reactive oxygen
species. J Immunol. 172:989–999. 2004.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Nagaraj S, Gupta K, Pisarev V, Kinarsky L,
Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI: Altered
recognition of antigen is a mechanism of CD8+ T cell tolerance in
cancer. Nat Med. 13:828–835. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
121
|
Hanson EM, Clements VK, Sinha P, Ilkovitch
D and Ostrand-Rosenberg S: Myeloid-derived suppressor cells
down-regulate L-selectin expression on CD4+ and CD8+ T cells. J
Immunol. 183:937–944. 2009.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Saleem SJ, Martin RK, Morales JK, Sturgill
JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ and Conrad DH:
Cutting edge: Mast cells critically augment myeloid-derived
suppressor cell activity. J Immunol. 189:511–515. 2012.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Oshi M, Asaoka M, Tokumaru Y, Yan L,
Matsuyama R, Ishikawa T, Endo I and Takabe K: CD8 T cell score as a
prognostic biomarker for triple negative breast cancer. Int J Mol
Sci. 21(6968)2020.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Peiper M, Goedegebuure PS, Linehan DC,
Ganguly E, Douville CC and Eberlein TJ: The HER2/neu-derived
peptide p654-662 is a tumor-associated antigen in human pancreatic
cancer recognized by cytotoxic T lymphocytes. Eur J Immunol.
27:1115–1123. 1997.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick
R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al:
Myeloid-derived suppressor cells enhance stemness of cancer cells
by inducing microRNA101 and suppressing the corepressor CtBP2.
Immunity. 39:611–621. 2013.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Horikawa N, Abiko K, Matsumura N,
Hamanishi J, Baba T, Yamaguchi K, Yoshioka Y, Koshiyama M and
Konishi I: Expression of Vascular Endothelial Growth Factor in
Ovarian Cancer Inhibits Tumor Immunity through the Accumulation
ofMyeloid-Derived Suppressor Cells. Clinical Cancer Research.
23:2017.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Vanderstraeten A, Luyten C, Verbist G,
Tuyaerts S and Amant F: Mapping the immunosuppressive environment
in uterine tumors: Implications for immunotherapy. Cancer Immunol
Immunother. 63:545–557. 2014.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Kawano M, Mabuchi S, Matsumoto Y, Sasano
T, Takahashi R, Kuroda H, Kozasa K, Hashimoto K, Isobe A, Sawada K,
et al: The significance of G-CSF expression and myeloid-derived
suppressor cells in the chemoresistance of uterine cervical cancer.
Sci Rep. 5(18217)2015.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Kusuda T, Shigemasa K, Arihiro K, Fujii T,
Nagai N and Ohama K: Relative expression levels of Th1 and Th2
cytokine mRNA are independent prognostic factors in patients with
ovarian cancer. Oncol Rep. 13:1153–1158. 2005.PubMed/NCBI
|
|
130
|
Tsukui T, Hildesheim A, Schiffman MH,
Lucci J III, Contois D, Lawler P, Rush BB, Lorincz AT, Corrigan A,
Burk RD, et al: Interleukin 2 production in vitro by peripheral
lymphocytes in response to human papillomavirus-derived peptides:
Correlation with cervical pathology. Cancer Res. 56:3967–3974.
1996.PubMed/NCBI
|
|
131
|
Chang WC, Li CH, Huang SC, Chang DY, Chou
LY and Sheu BC: Clinical significance of regulatory T cells and
CD8+ effector populations in patients with human endometrial
carcinoma. Cancer. 116:5777–5788. 2010.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Dutsch-Wicherek MM, Szubert S, Dziobek K,
Wisniewski M, Lukaszewska E, Wicherek L, Jozwicki W, Rokita W and
Koper K: Analysis of the treg cell population in the peripheral
blood of ovarian cancer patients in relation to the long-term
outcomes. Ginekol Pol. 90:179–184. 2019.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Hou F, Li Z, Ma D, Zhang W, Zhang Y, Zhang
T, Kong B and Cui B: Distribution of Th17 cells and
Foxp3-expressing T cells in tumor-infiltrating lymphocytes in
patients with uterine cervical cancer. Clin Chim Acta.
413:1848–1854. 2012.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Visser J, Nijman HW, Hoogenboom BN, Jager
P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, van der Zee
AG and Daemen T: Frequencies and role of regulatory T cells in
patients with (pre)malignant cervical neoplasia. Clin Exp Immunol.
150:199–209. 2007.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Mustea A, Braicu EI, Koensgen D, Yuan S,
Sun PM, Stamatian F, Lichtenegger W, Chen FC, Chekerov R and
Sehouli J: Monitoring of IL-10 in the serum of patients with
advanced ovarian cancer: Results from a prospective pilot-study.
Cytokine. 45:8–11. 2009.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A
and Di W: A high M1/M2 ratio of tumor-associated macrophages is
associated with extended survival in ovarian cancer patients. J
Ovarian Res. 7(19)2014.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Lan C, Huang X, Lin S, Huang H, Cai Q, Wan
T, Lu J and Liu J: Expression of M2-polarized macrophages is
associated with poor prognosis for advanced epithelial ovarian
cancer. Technol Cancer Res Treat. 12:259–267. 2013.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Hashimoto I, Kodama J, Seki N, Hongo A,
Miyagi Y, Yoshinouchi M and Kudo T: Macrophage infiltration and
angiogenesis in endometrial cancer. Anticancer Res. 20
(6C):853–856. 2000.PubMed/NCBI
|
|
139
|
Ding H, Cai J, Mao M, Fang Y, Huang Z, Jia
J, Li T, Xu L, Wang J, Zhou J, et al: Tumor-associated macrophages
induce lymphangiogenesis in cervical cancer via interaction with
tumor cells. APMIS. 122:1059–1069. 2014.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Chen XJ, Han LF, Wu XG, Wei WF, Wu LF, Yi
HY, Yan RM, Bai XY, Zhong M, Yu YH, et al: Clinical Significance of
CD163+ and CD68+ tumor-associated macrophages in high-risk
HPV-related cervical cancer. J Cancer. 8:3868–3875. 2017.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Lai P, Rabinowich H, Crowley-Nowick PA,
Bell MC, Mantovani G and Whiteside TL: Alterations in expression
and function of signal transducing proteins in tumor-associated T
and natural killer cells in ovarian carcinoma. Biochem Soc Trans.
25(218S)1997.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Gras Navarro A, Björklund AT and Chekenya
M: Therapeutic potential and challenges of natural killer cells in
treatment of solid tumors. Front Immunol. 6(202)2015.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Wu Y, Ye S, Goswami S, Pei X, Xiang L,
Zhang X and Yang H: Clinical significance of peripheral blood and
tumor tissue lymphocyte subsets in cervical cancer patients. BMC
Cancer. 20(173)2020.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Iva T, Lenka K, Michal H, Petr S, Jan L,
Ladislav P, et al: Mature dendritic cells correlate with favorable
immune infiltrate and improved prognosis in ovarian carcinoma
patients. Journal for Immunotherapy of Cancer. 6:2018.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Lijun Z, Xin Z, Danhua S, Xiaoping L,
Jianliu W, Huilan W and Lihui W: Tumor-Infiltrating Dendritic Cells
May Be Used as Clinicopathologic Prognostic Factors in Endometrial
Carcinoma. Int J Gynecol Cancer. 22:836–841. 2012.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Mendoza L, Bubeník J, Símová J, Korb J,
Bieblová J, Vonka V, Indrová M, Mikysková R and Jandlová T:
Tumour-inhibitory effects of dendritic cells administered at the
site of HPV 16-induced neoplasms. Folia Biol (Praha). 48:114–119.
2002.PubMed/NCBI
|
|
147
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone
C, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a
high CD8+/regulatory T cell ratio are associated with favorable
prognosis in ovarian cancer. Proc Natl Acad Sci USA.
102:18538–18543. 2005.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Kondratiev S, Sabo E, Yakirevich E, Lavie
O and Resnick MB: Intratumoral CD8+ T lymphocytes as a prognostic
factor of survival in endometrial carcinoma. Clin Cancer Res.
10:4450–4456. 2004.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Ordoñez R, Henríquez-Hernández LA,
Federico M, Valenciano A, Pinar B, Lloret M, Bordón E,
Rodríguez-Gallego C and Lara PC: Radio-induced apoptosis of
peripheral blood CD8 T lymphocytes is a novel prognostic factor for
survival in cervical carcinoma patients. Strahlenther Onkol.
190:210–216. 2014.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Miyasaka Y, Yoshimoto Y, Murata K, Noda
SE, Ando K, Ebara T, Okonogi N, Kaminuma T, Yamada S, Ikota H, et
al: Treatment outcomes of patients with adenocarcinoma of the
uterine cervix after definitive radiotherapy and the prognostic
impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment
biopsy specimens: A multi-institutional retrospective study. J
Radiat Res. 61:275–284. 2020.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Spiess PJ, Yang JC and Rosenberg SA: In
vivo antitumor activity of tumor-infiltrating lymphocytes expanded
in recombinant interleukin-2. J Natl Cancer Inst. 79:1067–1075.
1987.PubMed/NCBI
|
|
152
|
Krishna S, Lowery FJ, Copeland AR,
Bahadiroglu E, Mukherjee R, Jia L, Anibal JT, Sachs A, Adebola SO,
Gurusamy D, et al: Stem-like CD8 T cells mediate response of
adoptive cell immunotherapy against human cancer. Science.
370:1328–1334. 2020.PubMed/NCBI View Article : Google Scholar
|
|
153
|
J SP, C YJ and RS: In vivo
antitumor activity of tumor-infiltrating lymphocytes expanded in
recombinant interleukin-2. Journal of the National Cancer
Institute. 79:1987.PubMed/NCBI
|
|
154
|
Kumar A, Watkins R and Vilgelm AE: Cell
therapy with TILs: Training and taming T cells to fight cancer.
Front Immunol. 12(690499)2021.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Rohaan MW, Wilgenhof S and Haanen JBAG:
Adoptive cellular therapies: The current landscape. Virchows Arch.
474:449–461. 2018.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Gudiol C, Lewis RE, Strati P and
Kontoyiannis DP: Chimeric antigen receptor T-cell therapy for the
treatment of lymphoid malignancies: Is there an excess risk for
infection? Lancet Haematol. 8:e216–e228. 2021.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Rosenberg SA, Yang JC, Sherry RM, Kammula
US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF,
Wunderlich JR, et al: Durable complete responses in heavily
pretreated patients with metastatic melanoma using T-cell transfer
immunotherapy. Clin Cancer Res. 17:4550–4457. 2011.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Andersen R, Donia M, Ellebaek E, Borch TH,
Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH,
et al: Long-Lasting complete responses in patients with metastatic
melanoma after adoptive cell therapy with tumor-infiltrating
lymphocytes and an attenuated IL2 regimen. Clin Cancer Res.
22:3734–3745. 2016.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Stevanović S, Draper LM, Langhan MM,
Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry
RM, Kammula US, et al: Complete regression of metastatic cervical
cancer after treatment with human papillomavirus-targeted
tumor-infiltrating T cells. J Clin Oncol. 33:1543–1550.
2015.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Donnem T, Hald SM, Paulsen E, Richardsen
E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M,
Poehl M, et al: Stromal CD8+ T-cell Density-A promising supplement
to TNM staging in non-small cell lung cancer. Clin Cancer Res.
21:2635–2643. 2015.PubMed/NCBI View Article : Google Scholar
|
|
161
|
James FR, Jiminez-Linan M, Alsop J, Mack
M, Song H, Brenton JD, Pharoah PDP and Ali HR: Association between
tumour infiltrating lymphocytes, histotype and clinical outcome in
epithelial ovarian cancer. BMC Cancer. 17(657)2017.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Stanton SE and Disis ML: Clinical
significance of tumor-infiltrating lymphocytes in breast cancer. J
Immunother Cancer. 4(59)2016.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Sideras K, Biermann K, Yap K, Mancham S,
Boor PPC, Hansen BE, Stoop HJA, Peppelenbosch MP, van Eijck CH,
Sleijfer S, et al: Tumor cell expression of immune inhibitory
molecules and tumor-infiltrating lymphocyte count predict
cancer-specific survival in pancreatic and ampullary cancer. Int J
Cancer. 141:572–582. 2017.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Clemente O, Ottaiano A, Di Lorenzo G,
Bracigliano A, Lamia S, Cannella L, Pizzolorusso A, Di Marzo M,
Santorsola M, De Chiara A, et al: Is immunotherapy in the future of
therapeutic management of sarcomas? J Transl Med.
19(173)2021.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Radvanyi LG: Tumor-Infiltrating lymphocyte
therapy: Addressing prevailing questions. Cancer J. 21:450–464.
2015.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Aoki Y, Takakuwa K, Kodama S, Tanaka K,
Takahashi M, Tokunaga A and Takahashi T: Use of adoptive transfer
of tumor-infiltrating lymphocytes alone or in combination with
cisplatin-containing chemotherapy in patients with epithelial
ovarian cancer. Cancer Res. 51:1934–1939. 1991.PubMed/NCBI
|
|
167
|
Fujita K, Ikarashi H, Takakuwa K, Kodama
S, Tokunaga A, Takahashi T and Tanaka K: Prolonged disease-free
period in patients with advanced epithelial ovarian cancer after
adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer
Res. 1:501–507. 1995.PubMed/NCBI
|
|
168
|
Santoiemma PP and Powell DJ Jr: Tumor
infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther.
16:807–820. 2015.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Jazaeri AA, Zsiros E, Amaria RN, Artz AS,
Edwards RP, Wenham RM, Slomovitz BM, Walther A, Thomas SS, Chesney
JA, et al: Safety and efficacy of adoptive cell transfer using
autologous tumor infiltrating lymphocytes (LN-145) for treatment of
recurrent, metastatic, or persistent cervical carcinoma. J Clin
Oncol. 37 (15_suppl)(S2538)2019.
|
|
170
|
KF HI, KT SK, AT TT, et al: Prolonged
disease-free period in patients with advanced epithelial ovarian
cancer after adoptive transfer of tumor-infiltrating lymphocytes. J
Clinical Cancer Research: An Official Journal of the American
Association for Cancer Research 1, 1995.
|
|
171
|
Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki
O, Yunger S, Markel G, Schachter J and Besser MJ: Selection of
shared and neoantigen-reactive T cells for adoptive cell therapy
based on CD137 separation. Front Immunol. 8(1211)2017.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Inozume T, Hanada K, Wang QJ, Ahmadzadeh
M, Wunderlich JR, Rosenberg SA and Yang JC: Selection of CD8+PD-1+
lymphocytes in fresh human melanomas enriches for tumor-reactive T
cells. J Immunother. 33:956–964. 2010.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Manson G, Norwood J, Marabelle A, Kohrt H
and Houot R: Biomarkers associated with checkpoint inhibitors. Ann
Oncol. 27:1199–1206. 2016.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Wolf B, Zimmermann S, Arber C, Irving M,
Trueb L and Coukos G: Safety and tolerability of adoptive cell
therapy in cancer. Drug Saf. 42:315–334. 2019.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Burger SR: Current regulatory issues in
cell and tissue therapy. Cytotherapy. 5:289–298. 2003.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Cruz CR, Hanley PJ, Liu H, Torrano V, Lin
YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, et al:
Adverse events following infusion of T cells for adoptive
immunotherapy: A 10-year experience. Cytotherapy. 12:743–749.
2010.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Dudley ME, Wunderlich JR, Robbins PF, Yang
JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP,
Hubicki AM, et al: Cancer regression and autoimmunity in patients
after clonal repopulation with antitumor lymphocytes. Science.
298:850–854. 2002.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Shimabukuro-Vornhagen A, Gödel P, Subklewe
M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B and von
Bergwelt-Baildon MS: Cytokine release syndrome. J Immunother
Cancer. 6(56)2018.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Liu D and Zhao J: Cytokine release
syndrome: Grading, modeling, and new therapy. J Hematol Oncol.
11(121)2018.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM,
Yu BT and Wu N: Chimeric antigen receptor T-Cell therapy in lung
cancer: Potential and challenges. Front Immunol.
12(782775)2021.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Stevanović S, Pasetto A, Helman SR,
Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff
CA, Rosenberg SA and Hinrichs CS: Landscape of immunogenic tumor
antigens in successful immunotherapy of virally induced epithelial
cancer. Science. 356:200–205. 2017.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Disis ML, Dang Y, Coveler AL, Marzbani E,
Kou ZC, Childs JS, Fintak P, Higgins DM, Reichow J, Waisman J and
Salazar LG: HER-2/neu vaccine-primed autologous T-cell infusions
for the treatment of advanced stage HER-2/neu expressing cancers.
Cancer Immunol Immunother. 63:101–109. 2014.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Kyi C, Doubrovina E, Zhou Q, Kravetz S,
Iasonos A, Aghajanian C, Sabbatini P, Spriggs D, O'Reilly RJ and
O'Cearbhaill RE: Phase I dose escalation safety and feasibility
study of autologous WT1-sensitized T cells for the treatment of
patients with recurrent ovarian cancer. J Immunother Cancer.
9(e002752)2021.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Zacharakis N, Huq LM, Seitter SJ, Kim SP,
Gartner JJ, Sindiri S, Hill VK, Li YF, Paria BC, Ray S, et al:
Breast cancers are immunogenic: Immunologic analyses and a phase II
pilot clinical trial using mutation-reactive autologous
lymphocytes. J Clin Oncol. 40:1741–1754. 2022.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Westergaard MCW, Andersen R, Chong C,
Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G,
Bassani-Sternberg M, et al: Tumour-reactive T cell subsets in the
microenvironment of ovarian cancer. Br J Cancer. 120:424–434.
2019.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Tsimberidou AM, Guenther K, Andersson BS,
Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A,
Richter F, et al: Feasibility and safety of personalized,
multi-target, adoptive cell therapy (IMA101): First-In-Human
clinical trial in patients with advanced metastatic cancer. Cancer
Immunol Res. 11:925–945. 2023.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Stevanović S, Helman SR, Wunderlich JR,
Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA,
Kammula US, Sherry RM, et al: A phase II study of
tumor-infiltrating lymphocyte therapy for human
papillomavirus-associated epithelial cancers. Clin Cancer Res.
25:1486–1493. 2019.PubMed/NCBI View Article : Google Scholar
|
